Loading…
Oral anticoagulation in paediatric patients: dose requirements and complications
The lack of oral anticoagulant guidelines specific to paediatric practice has led to the adoption of adult regimens, often without scientific evidence of efficacy or safety. A two year prospective study of anticoagulant control was carried out in 45 children aged 9 months to 18 years, the majority o...
Saved in:
Published in: | Archives of disease in childhood 1996-03, Vol.74 (3), p.228-231 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3 |
---|---|
cites | cdi_FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3 |
container_end_page | 231 |
container_issue | 3 |
container_start_page | 228 |
container_title | Archives of disease in childhood |
container_volume | 74 |
creator | Tait, R C Ladusans, E J El-Metaal, M Patel, R G Will, A M |
description | The lack of oral anticoagulant guidelines specific to paediatric practice has led to the adoption of adult regimens, often without scientific evidence of efficacy or safety. A two year prospective study of anticoagulant control was carried out in 45 children aged 9 months to 18 years, the majority of whom were receiving primary prophylactic anticoagulation. The main indication was congenital heart disease, either with (n = 8) or without (n = 34) mechanical valve prosthesis. During a follow up period of 602 patient months the average interval between visits was three weeks. Target international normalised ratios (INRs) were achieved on 62% and 39% of visits for children with low target INR (2.0-3.0) and high target INR (3.0-4.0) respectively. However warfarin dose was altered on only 22% of visits. Warfarin doses required to achieve a stable INR of 2.0-3.0 in 33 children were strongly correlated with weight [dose (mg/d) = 0.07 x weight (kg) + 0.54] but independently influenced by age. No thrombotic complications were recorded, and haemorrhagic events were infrequent (2.1% of visits) and, with one exception, minor. Safe outpatient oral anticoagulation is feasible in children, whose warfarin requirements appear moderately predictable and whose control is no more erratic than that of adults. |
doi_str_mv | 10.1136/adc.74.3.228 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1511432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3968705531</sourcerecordid><originalsourceid>FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoWh87t8KACzdOzWsmqQtBilWh-AAVcROSTKKpnUlNZkT_vdGWohtXueR899x7DwC7CPYRIuWRrHSf0T7pY8xXQA_RkucYUroKehBCkg845xtgM8YJhAhzTtbBOmecUcx74OY6yGkmm9ZpL5-7qWydbzLXZDNpKifb4HQqW2eaNh5nlY8mC-atc8HU31-ps8q0r2dTp39a4zZYs3Iazc7i3QL3o7O74UU-vj6_HJ6Oc0UZa3NiEMaFLK3FlHGuC1opDgeWKSiNoarSsLKaYpUukbpA1EIFrSm1KrEprCVb4GTuO-tUbSqdtkmXiFlwtQyfwksn_iqNexHP_l2gAiFKcDLYXxgE_9aZ2IqJ70KTdhaIlQNGMB_wRB3OKR18jMHY5QQExXf8IsUvGBVEpPgTvvd7qyW8yDvp-Vx3sTUfS1mGV1Eywgpx9TBMbo_j89HoSdwm_mDOq3ry_-Qv-VSfTw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1769732898</pqid></control><display><type>article</type><title>Oral anticoagulation in paediatric patients: dose requirements and complications</title><source>Education Collection (Proquest) (PQ_SDU_P3)</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><source>PubMed</source><creator>Tait, R C ; Ladusans, E J ; El-Metaal, M ; Patel, R G ; Will, A M</creator><creatorcontrib>Tait, R C ; Ladusans, E J ; El-Metaal, M ; Patel, R G ; Will, A M</creatorcontrib><description>The lack of oral anticoagulant guidelines specific to paediatric practice has led to the adoption of adult regimens, often without scientific evidence of efficacy or safety. A two year prospective study of anticoagulant control was carried out in 45 children aged 9 months to 18 years, the majority of whom were receiving primary prophylactic anticoagulation. The main indication was congenital heart disease, either with (n = 8) or without (n = 34) mechanical valve prosthesis. During a follow up period of 602 patient months the average interval between visits was three weeks. Target international normalised ratios (INRs) were achieved on 62% and 39% of visits for children with low target INR (2.0-3.0) and high target INR (3.0-4.0) respectively. However warfarin dose was altered on only 22% of visits. Warfarin doses required to achieve a stable INR of 2.0-3.0 in 33 children were strongly correlated with weight [dose (mg/d) = 0.07 x weight (kg) + 0.54] but independently influenced by age. No thrombotic complications were recorded, and haemorrhagic events were infrequent (2.1% of visits) and, with one exception, minor. Safe outpatient oral anticoagulation is feasible in children, whose warfarin requirements appear moderately predictable and whose control is no more erratic than that of adults.</description><identifier>ISSN: 0003-9888</identifier><identifier>EISSN: 1468-2044</identifier><identifier>DOI: 10.1136/adc.74.3.228</identifier><identifier>PMID: 8787428</identifier><identifier>CODEN: ADCHAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><subject>Adolescent ; Aged ; Aged, 80 and over ; Anticoagulants ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Body Weight ; Cardiovascular diseases ; Child ; Child, Preschool ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Heart Defects, Congenital - surgery ; Heart Valve Prosthesis ; Humans ; Infant ; Male ; Middle Aged ; Prospective Studies ; Thromboembolism - prevention & control ; Warfarin - administration & dosage ; Warfarin - adverse effects ; Warfarin - therapeutic use</subject><ispartof>Archives of disease in childhood, 1996-03, Vol.74 (3), p.228-231</ispartof><rights>Copyright BMJ Publishing Group LTD Mar 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3</citedby><cites>FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1769732898/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1769732898?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,21378,21394,27924,27925,33611,33877,43733,43880,53791,53793,74093,74269</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8787428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tait, R C</creatorcontrib><creatorcontrib>Ladusans, E J</creatorcontrib><creatorcontrib>El-Metaal, M</creatorcontrib><creatorcontrib>Patel, R G</creatorcontrib><creatorcontrib>Will, A M</creatorcontrib><title>Oral anticoagulation in paediatric patients: dose requirements and complications</title><title>Archives of disease in childhood</title><addtitle>Arch Dis Child</addtitle><description>The lack of oral anticoagulant guidelines specific to paediatric practice has led to the adoption of adult regimens, often without scientific evidence of efficacy or safety. A two year prospective study of anticoagulant control was carried out in 45 children aged 9 months to 18 years, the majority of whom were receiving primary prophylactic anticoagulation. The main indication was congenital heart disease, either with (n = 8) or without (n = 34) mechanical valve prosthesis. During a follow up period of 602 patient months the average interval between visits was three weeks. Target international normalised ratios (INRs) were achieved on 62% and 39% of visits for children with low target INR (2.0-3.0) and high target INR (3.0-4.0) respectively. However warfarin dose was altered on only 22% of visits. Warfarin doses required to achieve a stable INR of 2.0-3.0 in 33 children were strongly correlated with weight [dose (mg/d) = 0.07 x weight (kg) + 0.54] but independently influenced by age. No thrombotic complications were recorded, and haemorrhagic events were infrequent (2.1% of visits) and, with one exception, minor. Safe outpatient oral anticoagulation is feasible in children, whose warfarin requirements appear moderately predictable and whose control is no more erratic than that of adults.</description><subject>Adolescent</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Body Weight</subject><subject>Cardiovascular diseases</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart Defects, Congenital - surgery</subject><subject>Heart Valve Prosthesis</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Thromboembolism - prevention & control</subject><subject>Warfarin - administration & dosage</subject><subject>Warfarin - adverse effects</subject><subject>Warfarin - therapeutic use</subject><issn>0003-9888</issn><issn>1468-2044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>CJNVE</sourceid><sourceid>M0P</sourceid><recordid>eNp9kEtLAzEUhYMoWh87t8KACzdOzWsmqQtBilWh-AAVcROSTKKpnUlNZkT_vdGWohtXueR899x7DwC7CPYRIuWRrHSf0T7pY8xXQA_RkucYUroKehBCkg845xtgM8YJhAhzTtbBOmecUcx74OY6yGkmm9ZpL5-7qWydbzLXZDNpKifb4HQqW2eaNh5nlY8mC-atc8HU31-ps8q0r2dTp39a4zZYs3Iazc7i3QL3o7O74UU-vj6_HJ6Oc0UZa3NiEMaFLK3FlHGuC1opDgeWKSiNoarSsLKaYpUukbpA1EIFrSm1KrEprCVb4GTuO-tUbSqdtkmXiFlwtQyfwksn_iqNexHP_l2gAiFKcDLYXxgE_9aZ2IqJ70KTdhaIlQNGMB_wRB3OKR18jMHY5QQExXf8IsUvGBVEpPgTvvd7qyW8yDvp-Vx3sTUfS1mGV1Eywgpx9TBMbo_j89HoSdwm_mDOq3ry_-Qv-VSfTw</recordid><startdate>19960301</startdate><enddate>19960301</enddate><creator>Tait, R C</creator><creator>Ladusans, E J</creator><creator>El-Metaal, M</creator><creator>Patel, R G</creator><creator>Will, A M</creator><general>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88I</scope><scope>8A4</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>19960301</creationdate><title>Oral anticoagulation in paediatric patients: dose requirements and complications</title><author>Tait, R C ; Ladusans, E J ; El-Metaal, M ; Patel, R G ; Will, A M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adolescent</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Body Weight</topic><topic>Cardiovascular diseases</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart Defects, Congenital - surgery</topic><topic>Heart Valve Prosthesis</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Thromboembolism - prevention & control</topic><topic>Warfarin - administration & dosage</topic><topic>Warfarin - adverse effects</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tait, R C</creatorcontrib><creatorcontrib>Ladusans, E J</creatorcontrib><creatorcontrib>El-Metaal, M</creatorcontrib><creatorcontrib>Patel, R G</creatorcontrib><creatorcontrib>Will, A M</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Education Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Education Database (ProQuest)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of disease in childhood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tait, R C</au><au>Ladusans, E J</au><au>El-Metaal, M</au><au>Patel, R G</au><au>Will, A M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral anticoagulation in paediatric patients: dose requirements and complications</atitle><jtitle>Archives of disease in childhood</jtitle><addtitle>Arch Dis Child</addtitle><date>1996-03-01</date><risdate>1996</risdate><volume>74</volume><issue>3</issue><spage>228</spage><epage>231</epage><pages>228-231</pages><issn>0003-9888</issn><eissn>1468-2044</eissn><coden>ADCHAK</coden><abstract>The lack of oral anticoagulant guidelines specific to paediatric practice has led to the adoption of adult regimens, often without scientific evidence of efficacy or safety. A two year prospective study of anticoagulant control was carried out in 45 children aged 9 months to 18 years, the majority of whom were receiving primary prophylactic anticoagulation. The main indication was congenital heart disease, either with (n = 8) or without (n = 34) mechanical valve prosthesis. During a follow up period of 602 patient months the average interval between visits was three weeks. Target international normalised ratios (INRs) were achieved on 62% and 39% of visits for children with low target INR (2.0-3.0) and high target INR (3.0-4.0) respectively. However warfarin dose was altered on only 22% of visits. Warfarin doses required to achieve a stable INR of 2.0-3.0 in 33 children were strongly correlated with weight [dose (mg/d) = 0.07 x weight (kg) + 0.54] but independently influenced by age. No thrombotic complications were recorded, and haemorrhagic events were infrequent (2.1% of visits) and, with one exception, minor. Safe outpatient oral anticoagulation is feasible in children, whose warfarin requirements appear moderately predictable and whose control is no more erratic than that of adults.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</pub><pmid>8787428</pmid><doi>10.1136/adc.74.3.228</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-9888 |
ispartof | Archives of disease in childhood, 1996-03, Vol.74 (3), p.228-231 |
issn | 0003-9888 1468-2044 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1511432 |
source | Education Collection (Proquest) (PQ_SDU_P3); Social Science Premium Collection (Proquest) (PQ_SDU_P3); PubMed |
subjects | Adolescent Aged Aged, 80 and over Anticoagulants Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - therapeutic use Body Weight Cardiovascular diseases Child Child, Preschool Drug Administration Schedule Female Follow-Up Studies Heart Defects, Congenital - surgery Heart Valve Prosthesis Humans Infant Male Middle Aged Prospective Studies Thromboembolism - prevention & control Warfarin - administration & dosage Warfarin - adverse effects Warfarin - therapeutic use |
title | Oral anticoagulation in paediatric patients: dose requirements and complications |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A57%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20anticoagulation%20in%20paediatric%20patients:%20dose%20requirements%20and%20complications&rft.jtitle=Archives%20of%20disease%20in%20childhood&rft.au=Tait,%20R%20C&rft.date=1996-03-01&rft.volume=74&rft.issue=3&rft.spage=228&rft.epage=231&rft.pages=228-231&rft.issn=0003-9888&rft.eissn=1468-2044&rft.coden=ADCHAK&rft_id=info:doi/10.1136/adc.74.3.228&rft_dat=%3Cproquest_pubme%3E3968705531%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b477t-3e1225a6ff24788c54db809f7b0aee4bdc0dfc42b204ac514f0b0fe6cb62e5ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1769732898&rft_id=info:pmid/8787428&rfr_iscdi=true |